Targeted proteomics of solid cancers: from quantification of known biomarkers towards reading the digital proteome maps

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14310%2F15%3A00081233" target="_blank" >RIV/00216224:14310/15:00081233 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00209805:_____/15:#0000650

Výsledek na webu

<a href="http://dx.doi.org/10.1586/14789450.2015.1094381" target="_blank" >http://dx.doi.org/10.1586/14789450.2015.1094381</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1586/14789450.2015.1094381" target="_blank" >10.1586/14789450.2015.1094381</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Targeted proteomics of solid cancers: from quantification of known biomarkers towards reading the digital proteome maps

Popis výsledku v původním jazyce

The concept of personalized medicine includes novel protein biomarkers that are expected to improve the early detection, diagnosis and therapy monitoring of malignant diseases. Tissues, biofluids, cell lines and xenograft models are the common sources ofbiomarker candidates that require verification of clinical value in independent patient cohorts. Targeted proteomics ? based on selected reaction monitoring, or data extraction from data-independent acquisition based digital maps ? now represents a promising mass spectrometry alternative to immunochemical methods. To date, it has been successfully used in a high number of studies answering clinical questions on solid malignancies: breast, colorectal, prostate, ovarian, endometrial, pancreatic, hepatocellular, lung, bladder and others. It plays an important role in functional proteomic experiments that include studying the role of post-translational modifications in cancer progression.

Název v anglickém jazyce

Targeted proteomics of solid cancers: from quantification of known biomarkers towards reading the digital proteome maps

Popis výsledku anglicky

The concept of personalized medicine includes novel protein biomarkers that are expected to improve the early detection, diagnosis and therapy monitoring of malignant diseases. Tissues, biofluids, cell lines and xenograft models are the common sources ofbiomarker candidates that require verification of clinical value in independent patient cohorts. Targeted proteomics ? based on selected reaction monitoring, or data extraction from data-independent acquisition based digital maps ? now represents a promising mass spectrometry alternative to immunochemical methods. To date, it has been successfully used in a high number of studies answering clinical questions on solid malignancies: breast, colorectal, prostate, ovarian, endometrial, pancreatic, hepatocellular, lung, bladder and others. It plays an important role in functional proteomic experiments that include studying the role of post-translational modifications in cancer progression.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

CE - Biochemie

OECD FORD obor

—

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>S - Specificky vyzkum na vysokych skolach<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2015

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Expert Review of Proteomics

ISSN

1478-9450

e-ISSN

—

Svazek periodika

12

Číslo periodika v rámci svazku

6

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

17

Strana od-do

651-667

Kód UT WoS článku

000364550700003

EID výsledku v databázi Scopus

—